Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 58

1.

Rapamycin Modulates Glucocorticoid Receptor Function, Blocks Atrophogene REDD1, and Protects Skin from Steroid Atrophy.

Lesovaya E, Agarwal S, Readhead B, Vinokour E, Baida G, Bhalla P, Kirsanov K, Yakubovskaya M, Platanias LC, Dudley JT, Budunova I.

J Invest Dermatol. 2018 Sep;138(9):1935-1944. doi: 10.1016/j.jid.2018.02.045. Epub 2018 Mar 27.

2.

Endogenous Glucocorticoid Deficiency in Psoriasis Promotes Inflammation and Abnormal Differentiation.

Sarkar MK, Kaplan N, Tsoi LC, Xing X, Liang Y, Swindell WR, Hoover P, Aravind M, Baida G, Clark M, Voorhees JJ, Nair RP, Elder JT, Budunova I, Getsios S, Gudjonsson JE.

J Invest Dermatol. 2017 Jul;137(7):1474-1483. doi: 10.1016/j.jid.2017.02.972. Epub 2017 Mar 1.

3.

Important role of kallikrein 6 for the development of keratinocyte proliferative resistance to topical glucocorticoids.

Kishibe M, Baida G, Bhalla P, Lavker RM, Schlosser B, Iinuma S, Yoshida S, Dudley JT, Budunova I.

Oncotarget. 2016 Oct 25;7(43):69479-69488. doi: 10.18632/oncotarget.9926.

4.

N-bromotaurine surrogates for loss of antiproliferative response and enhances cisplatin efficacy in cancer cells with impaired glucocorticoid receptor.

Logotheti S, Khoury N, Vlahopoulos SA, Skourti E, Papaevangeliou D, Liloglou T, Gorgoulis V, Budunova I, Kyriakopoulos AM, Zoumpourlis V.

Transl Res. 2016 Jul;173:58-73.e2. doi: 10.1016/j.trsl.2016.03.009. Epub 2016 Mar 21.

PMID:
27063960
5.

Selective Activator of the Glucocorticoid Receptor Compound A Dissociates Therapeutic and Atrophogenic Effects of Glucocorticoid Receptor Signaling in Skin.

Klopot A, Baida G, Bhalla P, Haegeman G, Budunova I.

J Cancer Prev. 2015 Dec;20(4):250-9. doi: 10.15430/JCP.2015.20.4.250. Epub 2015 Dec 30.

6.

Discovery of Compound A--a selective activator of the glucocorticoid receptor with anti-inflammatory and anti-cancer activity.

Lesovaya E, Yemelyanov A, Swart AC, Swart P, Haegeman G, Budunova I.

Oncotarget. 2015 Oct 13;6(31):30730-44. doi: 10.18632/oncotarget.5078. Review.

7.

REDD1 functions at the crossroads between the therapeutic and adverse effects of topical glucocorticoids.

Baida G, Bhalla P, Kirsanov K, Lesovaya E, Yakubovskaya M, Yuen K, Guo S, Lavker RM, Readhead B, Dudley JT, Budunova I.

EMBO Mol Med. 2015 Jan;7(1):42-58. doi: 10.15252/emmm.201404601.

8.

Asymmetric expression of connexins between luminal epithelial- and myoepithelial- cells is essential for contractile function of the mammary gland.

Mroue R, Inman J, Mott J, Budunova I, Bissell MJ.

Dev Biol. 2015 Mar 1;399(1):15-26. doi: 10.1016/j.ydbio.2014.11.026. Epub 2014 Dec 11.

9.

Combination of a selective activator of the glucocorticoid receptor Compound A with a proteasome inhibitor as a novel strategy for chemotherapy of hematologic malignancies.

Lesovaya E, Yemelyanov A, Kirsanov K, Popa A, Belitsky G, Yakubovskaya M, Gordon LI, Rosen ST, Budunova I.

Cell Cycle. 2013 Jan 1;12(1):133-44. doi: 10.4161/cc.23048. Epub 2012 Dec 19.

10.

Androgen receptor drives cellular senescence.

Mirochnik Y, Veliceasa D, Williams L, Maxwell K, Yemelyanov A, Budunova I, Volpert OV.

PLoS One. 2012;7(3):e31052. doi: 10.1371/journal.pone.0031052. Epub 2012 Mar 5.

11.

Differential targeting of androgen and glucocorticoid receptors induces ER stress and apoptosis in prostate cancer cells: a novel therapeutic modality.

Yemelyanov A, Bhalla P, Yang X, Ugolkov A, Iwadate K, Karseladze A, Budunova I.

Cell Cycle. 2012 Jan 15;11(2):395-406. doi: 10.4161/cc.11.2.18945. Epub 2012 Jan 15.

12.

Antitumor effect of non-steroid glucocorticoid receptor ligand CpdA on leukemia cell lines CEM and K562.

Lesovaya EA, Yemelyanov AY, Kirsanov KI, Yakubovskaya MG, Budunova IV.

Biochemistry (Mosc). 2011 Nov;76(11):1242-52. doi: 10.1134/S000629791111006X.

PMID:
22117551
13.

Overexpression of connexin26 in the basal keratinocytes reduces sensitivity to tumor promoter TPA.

Wang X, Ramirez A, Budunova I.

Exp Dermatol. 2010 Jul 1;19(7):633-40. doi: 10.1111/j.1600-0625.2009.01013.x. Epub 2009 Dec 7.

PMID:
20002174
14.

Targeting transcription factor NFkappaB: comparative analysis of proteasome and IKK inhibitors.

Gasparian AV, Guryanova OA, Chebotaev DV, Shishkin AA, Yemelyanov AY, Budunova IV.

Cell Cycle. 2009 May 15;8(10):1559-66. Epub 2009 May 13.

PMID:
19372735
15.

Novel steroid receptor phyto-modulator compound a inhibits growth and survival of prostate cancer cells.

Yemelyanov A, Czwornog J, Gera L, Joshi S, Chatterton RT Jr, Budunova I.

Cancer Res. 2008 Jun 15;68(12):4763-73. doi: 10.1158/0008-5472.CAN-07-6104.

16.

Epithelial cells in the hair follicle bulge do not contribute to epidermal regeneration after glucocorticoid-induced cutaneous atrophy.

Chebotaev DV, Yemelyanov AY, Lavker RM, Budunova IV.

J Invest Dermatol. 2007 Dec;127(12):2749-58. Epub 2007 Jul 26.

17.

The mechanisms of tumor suppressor effect of glucocorticoid receptor in skin.

Chebotaev D, Yemelyanov A, Budunova I.

Mol Carcinog. 2007 Aug;46(8):732-40. Review.

PMID:
17538956
18.

Androgen receptor targets NFkappaB and TSP1 to suppress prostate tumor growth in vivo.

Nelius T, Filleur S, Yemelyanov A, Budunova I, Shroff E, Mirochnik Y, Aurora A, Veliceasa D, Xiao W, Wang Z, Volpert OV.

Int J Cancer. 2007 Sep 1;121(5):999-1008.

19.

The tumor suppressor effect of the glucocorticoid receptor in skin is mediated via its effect on follicular epithelial stem cells.

Chebotaev D, Yemelyanov A, Zhu L, Lavker RM, Budunova I.

Oncogene. 2007 May 10;26(21):3060-8. Epub 2006 Dec 4.

PMID:
17146443
20.

Tumor suppressor activity of glucocorticoid receptor in the prostate.

Yemelyanov A, Czwornog J, Chebotaev D, Karseladze A, Kulevitch E, Yang X, Budunova I.

Oncogene. 2007 Mar 22;26(13):1885-96. Epub 2006 Oct 2.

PMID:
17016446

Supplemental Content

Loading ...
Support Center